This week, the ratings of three Pharmaceutical stocks on Portfolio Grader are down. Each of these rates a "D" ("sell") or "F" overall ("strong sell"). More
Nikkei: Aggressively Pulling Back, But Not Collapsing
The Nikkei's two-day bashing (and related drop in the EWJ) is jarring, but technical support should keep this dive from getting much hairier. More
5 Electrical Equipment Stocks to Sell Now
This week, the ratings of five Electrical Equipment stocks on Portfolio Grader are down. Each of these rates a "D" ("sell") or "F" overall ("strong sell"). More
Will ‘Sell in May and Go Away’ Take Hold in 2013 After All?
S&P 500 charts from the past decade illustrate why we shouldn't start panicking about the recent market turbulence. More
The Alchemy of Printing Without Ink
Ben Bernanke has succeeded to do what alchemists for millennia could not accomplish: produce something out of nothing, using a controversial tool called QE. More
The 2013 Retirement Portfolio Candidates: Starbucks
The king of coffee shops is in great shape, and has been for a few years. The stock is pricey, but might be right if you don't mind paying the premium. More
3 Under-the-Radar Services Stocks to Buy
Accenture gets all of the attention in the consulting sector, but these three less-ballyhooed stocks are better bargain buys given their growth potential. More
